Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNDP-001 in Idiopathic Parkinson's Disease
NCT07106021Phase 2Active, not recruiting
- Sponsor
- Kenai Therapeutics
- Start
- Jul 2025
- Primary completion
- Sep 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2 trial of RNDP-001 in Parkinson's disease (PD) (3 arms), sponsored by Kenai Therapeutics. Primary endpoint: Safety and Tolerability at 15 months. Started Jul 2025; status: active, not recruiting.
02
Drugs
RNDP-001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07106021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106021.